Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

14.07 -7.89 (-35.94%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny
FDA is investigating Sarepta's Elevidys after two deaths from liver failure in non-ambulatory DMD patients, raising safety and regulatory concerns. 
Via Benzinga
Topics Death
Sarepta Therapeutics Is Already Down 84% This Year. And The Other Shoe Just Dropped.
Shares were under pressure again Wednesday, deepening the 84% loss for the year, as the FDA planned the next steps for Elevidys. 
Via Investor's Business Daily
Topics Death
Sarepta Stock Slumps After FDA Opens Probe Into Patient Death, Analyst Sounds Alarm
H.C. Wainwright reiterated a ‘Sell’ rating on Sarepta on Wednesday with a $10 price target. The firm views the FDA as a potential headwind for Sarepta now. 
Via Stocktwits
Topics Artificial Intelligence Death
This Sarepta Therapeutics Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
Assessing Sarepta Therapeutics: Insights From 38 Financial Analysts
Via Benzinga
Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand
Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered revenue prospects. 
Via Benzinga
This Sarepta Therapeutics Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday
Via Benzinga
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
Nicole Verdun and Rachael Anatol were placed on administration leave without explanation. 
Via Investor's Business Daily
Topics Government
2 Growth Stocks with All-Star Potential and 1 to Ignore
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s... 
Via StockStory
Topics Artificial Intelligence
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences
After a second patient passed away, Sarepta Therapeutics crashed. Solid Biosciences rose over 10% in response. Wall Street sees big upside in both names. 
Via MarketBeat
Topics Earnings
US Stock Futures Tumble After Trump Threatens 'Real End' To Iran's Nuclear Problem: '...Avoid Getting Whipsawed By Noise,' Says Expert
U.S. stock futures were trading lower on Tuesday following Monday's advanced. Futures of major benchmark indices were lower in premarket. 
Via Benzinga
Topics Government
Market Monitor News June 17 (ROKU, Advanced Micro Devices UP - Sarepta Therapeutics DOWN)
Markets rebound on hopes of Iran de-escalation; oil drops, Roku surges on Amazon deal, Fed decision looms. 
Via Chartmill
Topics Economy
Dow Surges Over 300 Points As Iran Signals De-Escalation: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone
Via Benzinga
Topics Stocks
1 Oversold Stock Primed to Rebound and 2 to Steer Clear Of
The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling... 
Via StockStory
Monday's session: top gainers and losers
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
S&P 500 Surges 1%; New York Manufacturing Activity Tumbles In June
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
What the Options Market Tells Us About Sarepta Therapeutics
Via Benzinga
Why Sarepta Therapeutics (SRPT) Stock Is Down Today
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 44.4% in the afternoon session after the company reported a second death linked to its Duchenne muscular dystrophy gene therapy,.... 
Via StockStory
Top movers in Monday's session
Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
These stocks are gapping in today's session
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
US Stocks Higher; Dow Jumps Over 400 Points
Via Benzinga
Topics Stocks
This Sarepta Therapeutics Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Via Benzinga
Sarepta Therapeutics Stock Plunges On Multiple Downgrades Following Patient Death: Retail Questions ‘Crazy’ Price Targets
Piper Sandler cut its Elevidys peak sales estimate to $1.7 billion from $2.4 billion. 
Via Stocktwits
Topics Death
Sarepta Therapeutics Plummets 43% After A Second Gene Therapy Recipient Dies
The company is working with an independent group to determine if there's a better immunosuppressive regimen. 
Via Investor's Business Daily
Topics Death Government
Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Monday's pre-market session: top gainers and losers
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Dow Futures Edge Up As Israel-Iran Conflict Spares Oil Capacity: US Steel, Tesla, Victoria’s Secret, Sarepta Among Stocks To Watch
While Dow Jones futures gained 0.41% at the time of writing, the S&P 500 futures rose 0.48%. 
Via Stocktwits
Topics ETFs Government Stocks
Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy
Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and clinical trial pause. 
Via Benzinga
Topics Death
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback